SuperworthMcKesson EPS MCK
Diluted earnings per share by quarter and over the last twelve months, from 2008.
- Last 12 months, to Jun 30, 2026
- $37.35
- Latest quarter, Q1 FY27
- $5.15
- −18% on a year earlier
- Fiscal year 2026
- $38.45
- +49% on the year before
McKesson's earnings per share was $37.35 over the twelve months to Jun 30, 2026, up 49% on a year earlier.
In its latest quarter, Q1 FY27, it was $5.15, down 18% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2026 | $38.45 | +49% |
| FY2025 | $25.82 | +15% |
| FY2024 | $22.37 | −11% |
| FY2023 | $25.06 | +248% |
| FY2022 | $7.21 | n/a |
| FY2021 | −$28.62 | −658% |
| FY2020 | $5.13 | +8450% |
| FY2019 | $0.06 | −71% |
| FY2018 | $0.21 | −99% |
| FY2017 | $23.33 | +141% |
| FY2016 | $9.69 | +55% |
| FY2015 | $6.27 | +15% |
| FY2014 | $5.43 | −3% |
| FY2013 | $5.59 | −0% |
| FY2012 | $5.60 | +23% |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q1 FY27 | $5.15 | −18% | $37.35 | |
| Q4 FY26 | $13.69 | +37% | $38.45 | |
| Q3 FY26 | $9.59 | +38% | $34.76 | |
| Q2 FY26 | $8.92 | +377% | $32.12 | |
| Q1 FY26 | $6.25 | −11% | $25.07 | |
| Q4 FY25 | $10.00 | +66% | $25.82 | |
| Q3 FY25 | $6.95 | +57% | $21.83 | |
| Q2 FY25 | $1.87 | −62% | $19.30 | |
| Q1 FY25 | $7.00 | −0% | $22.35 | |
| Q4 FY24 | $6.01 | +5% | $22.37 | |
| Q3 FY24 | $4.42 | −42% | $22.08 | |
| Q2 FY24 | $4.92 | −23% | $25.32 |
Against its peers
Companies in Healthcare nearest McKesson's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| MCKMcKesson | $37.35 | +49% a year |
| SYKStryker | $9.65 | +28% a year |
| CVSCVS Health | $3.79 | +6% a year |
| MDTMedtronic | $4.07 | +12% a year |
| BMYBristol-Myers Squibb | $4.54 | +83% a year |
| VRTXVertex Pharmaceuticals | $17.18 | +23% a year |
| HCAHCA Healthcare | $29.87 | +26% a year |
| ELVElevance Health | $22.50 | −4% a year |
| ISRGIntuitive Surgical | $8.27 | +9% a year |
| DHRDanaher | $5.63 | +20% a year |
| REGNRegeneron Pharmaceuticals | $40.44 | +2% a year |
| Peer median | $8.96 |
Where McKesson ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on McKesson
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.